Asean nations urged to cooperate on lowering cost of next-gen drugs for HIV patients
KUCHING: Asean member states must work together to reduce the cost of next-generation antiretroviral (ARV) drugs for HIV patients in their respective countries, says Datuk Lukanisman Awang Sauni.
The Deputy Health Minister said regional cooperation was vital to procure these drugs at fair and affordable prices.
"The cost of ARV drugs is high due to their intellectual property, so we need to work together on regional procurement solutions.
"Buying in bulk through an Asean regional platform will facilitate easier access to these drugs," he told reporters after opening the Asean regional dialogue on affordable ARV drugs and promoting community-based testing here on Thursday (July 17).
Lukanisman also said Malaysia was working to reduce the cost of a new fixed-dose combination drug known as tenofovir-lamivudine-dolutegravir (TLD).
"The current ARV costs about RM500 a year. TLD is a new medicine that would cost over RM200 a month, but we want to reduce it to at least RM100 per month.
"The cost is higher than the previous ARV, but it's more effective in treating patients," he said.
In his speech earlier, Lukanisman said access to affordable next-generation ARV drugs like TLD was essential to sustain the HIV response in Asean countries.
However, he said the region was facing the twin challenges of declining international funding and increasing costs of providing HIV services.
"We must work together to pursue fair pricing, support voluntary licensing and develop regional procurement solutions through mechanisms like the Medicines Patent Pool," he said.
The Medicines Patent Pool is an international public health organisation that aims to increase access to essential medicines for low- and middle-income countries through voluntary licensing and patent pooling.
Lukanisman also said the dialogue was a platform to strengthen regional solidarity and reaffirm Asean's collective commitment to ending AIDS as a public health threat by 2030.
He said the experience and best practices of countries like Cambodia, Thailand, Vietnam and Malaysia could guide the way forward for the region.
"This dialogue enables us to learn from one another and coordinate efforts across Asean," he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sinar Daily
20 hours ago
- Sinar Daily
From Crisis to Collaboration: Why Harm Reduction is Malaysia's Public Health Opportunity
ALMOST two decades ago, I stood at the frontlines of Malaysia's HIV epidemic, a time when fear, stigma and silence ruled the discourse around drug use and HIV. The data was grim: some 70 per cent of new HIV infections were among people who inject drugs (PWIDs). We were losing lives, and our response was fragmented at best. We knew something had to change. What followed was bold and unprecedented. With the support of allies across the Health Ministry, civil society, law enforcement and religious leadership, we launched the Needle and Syringe Exchange Programme (NSEP) in 2006. At the time, it was politically unpopular. Critics worried it would condone drug use. But we persisted, because science and humanity demanded it. Today, the success is undeniable: HIV transmission among PWIDs and their partners has dropped dramatically. The NSEP saved lives and transformed mindsets. Yet despite this progress, the underlying policy framework that criminalises and marginalises people who use drugs remains largely intact. Malaysia's drug laws continue to emphasise punishment over rehabilitation, incarceration over care. We cannot meaningfully implement harm reduction while treating drug dependence as a moral failing or criminal offence. This is the core argument: drug policy reform is not just complementary to harm reduction, it is foundational to it. Without reforming our approach to drugs legally, institutionally and socially, our harm reduction efforts will always be constrained. We need a national paradigm shift from punitive drug control to public health-based policies. This means decriminalising personal drug use, investing in treatment and prevention services and empowering community-led initiatives. Other countries have taken this step and seen measurable public health and economic benefits. Portugal, for instance, decriminalised all drugs in 2001, and instead focused on harm reduction, treatment, and reintegration. As a result, drug-related deaths and HIV infections plummeted. Malaysia must take inspiration and adapt such evidence-based models to our context. And reform doesn't stop with laws. It requires strong political will, inter-agency collaboration and courage to lead with compassion. When we launched NSEP, success was only possible because of multisectoral alignment from theHealth Ministry to the police force, from NGOs to the Malaysian Islamic Development Department (JAKIM). This is the same spirit we must reignite for wider drug policy reform. Regulation, too, is essential. Harm reduction does not mean lack of control; it demands smart, risk-proportionate governance. Whether it's opioid substitution therapy or access to safer nicotine products, clear and evidence-based regulation ensures both public safety and access to lifesaving tools. This applies directly to Malaysia's fast-evolving tobacco and vape landscape. Overregulation can drive people to unregulated markets; underregulation risks misuse and public backlash. In line with public health objectives, tax rates on vape products should be increased relative to cigarettes and heated tobacco sticks. A balanced tax framework can discourage uptake among youth, align with harm reduction goals for smokers and generate revenue for health programs. - Bernama photo for illustration purpose only The middle path, characterised by firmly regulated but widely accessible harm reduction tools, is where real progress lies. This includes decisive measures such as banning high-risk open-system vape devices prone to adulteration, while maintaining strict controls on other products. Regulation should target illicit and poorly regulated outlets through enhanced enforcement without punishing law-abiding players who operate within compliance. Enforcement initiatives like Ops Selamat Paru-Paru (Ops Selamat Papa), recently launched by the Ministry of Health, are an encouraging sign that the government recognises the urgency of the issue. However, enforcement has always been the Achilles' heel of public health in Malaysia. Raids, confiscations and press conferences make headlines, but without sustained follow-through, the illicit market adapts and continues to thrive. For enforcement to succeed, it must be systematic, consistent, and paired with structural reforms: closing loopholes in licensing, disrupting illicit supply chains, and ensuring penalties are applied evenly. Otherwise, Ops Selamat Papa risks becoming another short-lived operation rather than a lasting pillar of harm reduction. Fiscal policy has a role too. In line with public health objectives, tax rates on vape products should be increased relative to cigarettes and heated tobacco sticks. A balanced tax framework can discourage uptake among youth, align with harm reduction goals for smokers and generate revenue for health programs. Equally important is the role of the private sector. I have seen firsthand how partnerships with foundations like Yayasan Sime Darby and corporate leaders such as Sunway Group have amplified impact in the HIV and health space. With strategic backing from the Finance Ministry, the private sector can support innovation, financing, and delivery of sustainable harm reduction programs. Religious authorities, particularly in Malaysia's Islamic context, have been instrumental in reframing harm reduction as a moral obligation to protect life. Fatwas and views that support methadone programs and needle exchanges helped legitimise these interventions within the Muslim community. This synergy between faith and evidence is uniquely Malaysian and powerful. This is why I founded HUMANIZE Malaysia. We are a bridge linking corporate actors, policymakers, civil society and communities to drive sustainable change. Our mission is to humanise health, to put people, not ideology, at the centre of policy. The broader opportunity is this: harm reduction must evolve into a cornerstone of Malaysia's public health strategy not just for HIV, but also for challenges like alcohol abuse, tobacco dependence, rising sugar consumption, and synthetic drug use. Every one of these issues shares a common truth: punitive responses fail. People do not need punishment they need options, support and dignity. Across the globe, countries that embraced harm reduction and reformed outdated drug laws are saving lives, reducing crime, and cutting costs. Japan's shift to heated tobacco products has already shown public health benefits and cost savings. In New Zealand, support for safer nicotine products helped halve adult smoking rates in just five years. Malaysia can and must, be a leader in this space. We already know what works. Data-led policy. Bold political leadership. Corporate partnership. Community empowerment. Religious engagement. These are not new ideas; they are proven ingredients. But they require one thing above all: the courage to shift from criminalising to caring. Let us not wait for another epidemic to force our hand. Let's build on our past successes. Let's expand harm reduction and truly put health and humanity first. Let's humanise policy. Let's humanise health. Bakhtiar Talhah is the CEO of HUMANIZE Malaysia, Trustee of the Malaysian AIDS Foundation and former President of the Malaysian AIDS Council. The views expressed in this article are his own and do not necessarily reflect those of Sinar Daily.
Malay Mail
4 days ago
- Malay Mail
From crisis to collaboration: Why harm reduction is Malaysia's public health opportunity — Bakhtiar Talhah
JULY 31 — Almost two decades ago, I stood at the frontlines of Malaysia's HIV epidemic — a time when fear, stigma and silence ruled the discourse around drug use and HIV. The data was grim: some 70 per cent of new HIV infections were among people who inject drugs (PWIDs). We were losing lives, and our response was fragmented at best. We knew something had to change. What followed was bold and unprecedented. With the support of allies across the Ministry of Health, civil society, law enforcement and religious leadership, we launched the Needle and Syringe Exchange Programme (NSEP) in 2006. At the time, it was politically unpopular. Critics worried it would condone drug use. But we persisted, because science and humanity demanded it. Today, the success is undeniable: HIV transmission among PWIDs and their partners has dropped dramatically. The NSEP saved lives — and transformed mindsets. Yet despite this progress, the underlying policy framework that criminalises and marginalises people who use drugs remains largely intact. Malaysia's drug laws continue to emphasise punishment over rehabilitation, incarceration over care. We cannot meaningfully implement harm reduction while treating drug dependence as a moral failing or criminal offence. This is the core argument: drug policy reform is not just complementary to harm reduction — it is foundational to it. Without reforming our approach to drugs — legally, institutionally, and socially — our harm reduction efforts will always be constrained. We need a national paradigm shift from punitive drug control to public health-based policies. This means decriminalising personal drug use, investing in treatment and prevention services, and empowering community-led initiatives. Other countries have taken this step — and seen measurable public health and economic benefits. Portugal, for instance, decriminalised all drugs in 2001, and instead focused on harm reduction, treatment, and reintegration. As a result, drug-related deaths and HIV infections plummeted. Malaysia must take inspiration and adapt such evidence-based models to our context. And reform doesn't stop with laws. It requires strong political will, inter-agency collaboration, and courage to lead with compassion. When we launched NSEP, success was only possible because of multisectoral alignment — from the Ministry of Health to the Royal Malaysian Police, from NGOs to the Malaysian Islamic Development Department (JAKIM). This is the same spirit we must reignite for wider drug policy reform. Regulation, too, is essential. Harm reduction does not mean lack of control — it demands smart, risk-proportionate governance. Whether it's opioid substitution therapy or access to safer nicotine products, clear and evidence-based regulation ensures both public safety and access to lifesaving tools. This applies directly to Malaysia's fast-evolving tobacco and vape landscape. Overregulation can drive people to unregulated markets; underregulation risks misuse and public backlash. The middle path — firmly regulated but widely accessible harm reduction tools — is where real progress lies. This includes decisive measures such as banning high-risk open-system vape devices prone to adulteration, while maintaining strict controls on other products. Regulation should target illicit and poorly regulated outlets through enhanced enforcement — without punishing law-abiding players who operate within compliance. Bakhtiar Talhah (second left) speaking on a HIV/AIDS advocacy programme. — Picture courtesy of Malaysian AIDS Foundation Enforcement initiatives like Ops Selamat Paru-Paru (Ops Selamat Papa), recently launched by the Ministry of Health, are an encouraging sign that the government recognises the urgency of the issue. However, enforcement has always been the Achilles' heel of public health in Malaysia. Raids, confiscations, and press conferences make headlines, but without sustained follow-through, the illicit market adapts and continues to thrive. For enforcement to succeed, it must be systematic, consistent, and paired with structural reforms: closing loopholes in licensing, disrupting illicit supply chains, and ensuring penalties are applied evenly. Otherwise, Ops Selamat Papa risks becoming another short-lived operation rather than a lasting pillar of harm reduction. Fiscal policy has a role too. In line with public health objectives, tax rates on vape products should be increased relative to cigarettes and heated tobacco sticks. A balanced tax framework can discourage uptake among youth, align with harm reduction goals for smokers, and generate revenue for health programmes. Equally important is the role of the private sector. I have seen firsthand how partnerships with foundations like Yayasan Sime Darby and corporate leaders such as Sunway Group have amplified impact in the HIV and health space. With strategic backing from the Ministry of Finance, the private sector can support innovation, financing, and delivery of sustainable harm reduction programmes. Religious authorities, particularly in Malaysia's Islamic context, have been instrumental in reframing harm reduction as a moral obligation to protect life. Fatwas and views that support methadone programmes and needle exchanges helped legitimise these interventions within the Muslim community. This synergy between faith and evidence is uniquely Malaysian — and powerful. This is why I founded Humanize Malaysia. We are a bridge — linking corporate actors, policymakers, civil society, and communities to drive sustainable change. Our mission is to humanise health, to put people — not ideology — at the centre of policy. The broader opportunity is this: harm reduction must evolve into a cornerstone of Malaysia's public health strategy — not just for HIV, but also for challenges like alcohol abuse, tobacco dependence, rising sugar consumption, and synthetic drug use. Every one of these issues shares a common truth: punitive responses fail. People do not need punishment — they need options, support, and dignity. Across the globe, countries that embraced harm reduction and reformed outdated drug laws are saving lives, reducing crime, and cutting costs. Japan's shift to heated tobacco products has already shown public health benefits and cost savings. In New Zealand, support for safer nicotine products helped halve adult smoking rates in just five years. Malaysia can, and must, be a leader in this space. We already know what works. Data-led policy. Bold political leadership. Corporate partnership. Community empowerment. Religious engagement. These are not new ideas — they are proven ingredients. But they require one thing above all: the courage to shift from criminalising to caring. Let us not wait for another epidemic to force our hand. Let's build on our past successes. Let's expand harm reduction and truly put health and humanity first. Let's humanise policy. Let's humanise health. * Bakhtiar Talhah is the CEO of Humanize Malaysia, trustee of the Malaysian AIDS Foundation, and former president of the Malaysian AIDS Council. ** This is the personal opinion of the writer or publication and does not necessarily represent the views of Malay Mail.
Barnama
5 days ago
- Barnama
Sunway Medical Centre Hosts International Symposium To Strengthen Regional Paediatric Care
KUALA LUMPUR, July 29 (Bernama) -- Sunway Medical Centre, Sunway City (SMC) has organised the International Paediatric Symposium 2025 from July 26 to 27, bringing together leading paediatric specialists from Malaysia, China, Singapore, and the United States (US). In a statement, SMC said the hybrid symposium, themed 'Paediatrics Without Borders: Bridging Subspecialties, Saving Lives', was officiated by Deputy Health Minister Datuk Lukanisman Awang Sauni and attended by the Director of the Health Performance Unit, Health Ministry Dr Saravanan SR Sundaramurthy. 'The symposium served as a vital platform for sharing expertise, advancing clinical practices and fostering global collaboration in children's healthcare,' it said. According to the statement, the symposium gathered paediatric specialists from SMC, Sunway Medical Centre Damansara (SMCD), Sunway Medical Centre Velocity (SMCV), Sunway Medical Centre Penang (SMCP), Sunway Medical Centre Ipoh (SMCI), Fudan Children's Hospital (Shanghai), Boston Children's Hospital (US), and KK Women's and Children's Hospital (Singapore). 'The event served as a powerful platform for knowledge exchange, evidence-based practice updates and regional standard-setting in paediatric care that goes beyond borders,' it said. A wide range of topics was discussed at the symposium, including critical newborn care, adolescent oncology, cardiac emergencies, and chronic conditions. 'A standout session on regional health equity sparked dynamic dialogue around how countries can work together to close gaps in access, boost training for paediatric subspecialties and implement early detection models that save lives,' the statement read. Sunway Medical Centre's Children's Health and Development Centre offered a wide range of paediatric subspecialties across multiple disciplines, with purpose-built facilities, child-friendly environments, and experienced multidisciplinary teams. The Centre is a regional leader in holistic, patient-centred care for children. As Malaysia's largest private quaternary hospital, SMC houses over 300 resident medical consultants, 60 medical specialities, and 28 Centres of Excellence, and upon completion of its sixth block-Tower F (Children's Pavilion), it will expand to over 1,100 beds from the current 810 licensed beds.
